Cardiff Oncology, Inc. (CRDF)Healthcare | Biotechnology | San Diego, United States | NasdaqCM
0.96 USD
-0.01
(-1.535%) ⇩
(Oct. 16, 2026, 11:47 a.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 3:16 a.m. EDT
The investment case for Cardiff Oncology is defined by a stark disconnect between its deteriorating business reality and speculative hopes for a clinical breakthrough. Fundamentally, the company is in distress: revenue has contracted by 14%, operating margins are catastrophic at -92%, and the stock has lost 99% of its value over the last nine years. The balance sheet is fragile, with massive free cash burn and negative returns on equity, leaving no safety net if the pipeline fails. While insider buying and a recent $10 million capital raise provide a temporary lifeline, these actions do not alter the structural decline evident in the price history. However, the options market tells a different story, positioning aggressively for a rally. The heavy concentration of call open interest at strikes significantly above the current price suggests traders are betting on a successful Phase II trial result or a strategic partnership announcement that could re-rate the entire asset. This speculative fervor creates a volatile, binary trading environment rather than a stable investment thesis. For the long term, the risk of permanent capital loss remains high given the lack of commercialized products and shrinking revenues. Short-term, the stock acts as a leveraged bet on a single clinical event, making it suitable only for high-risk speculation, not portfolio allocation. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.201192 |
| AutoETS | 0.212543 |
| AutoARIMA | 0.213212 |
| AutoTheta | 0.565809 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 30% |
| H-stat | 12.07 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.233 |
| Excess Kurtosis | -0.94 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.722 |
| Revenue per Share | 0.007 |
| Market Cap | 74,380,032 |
| Forward P/E | -1.79 |
| Beta | 1.42 |
| Website | https://www.cardiffoncology.com |
As of Oct. 10, 2026, 3:16 a.m. EDT: Options activity reveals a distinct bullish bias with heavy open interest in out-of-the-money calls (strikes $1.50 and $2.50) across multiple expirations, suggesting speculation on a significant upside move. Conversely, put volume is negligible and concentrated near the money, indicating minimal hedging against downside. Implied volatility is extremely low, reflecting a lack of pricing for a crash despite the company's precarious fundamentals.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.55707765 |
| Address1 | 11,055 Flintkote Avenue |
| All Time High | 2,030.4 |
| All Time Low | 0.7 |
| Ask | 1.02 |
| Ask Size | 1 |
| Audit Risk | 6 |
| Average Daily Volume10 Day | 450,900 |
| Average Daily Volume3 Month | 798,423 |
| Average Volume | 798,423 |
| Average Volume10Days | 450,900 |
| Beta | 1.418 |
| Bid | 1.11 |
| Bid Size | 3 |
| Board Risk | 2 |
| Book Value | 0.387 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.9561 |
| Current Ratio | 3.296 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 0.9949 |
| Day Low | 0.9501 |
| Debt To Equity | 1.722 |
| Display Name | Cardiff Oncology |
| Dividend Date | 1,550,620,800 |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,740,691,800 |
| Earnings Call Timestamp Start | 1,740,691,800 |
| Earnings Timestamp | 1,786,478,400 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -41,915,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.99 |
| Enterprise To Revenue | 81.646 |
| Enterprise Value | 41,476,188 |
| Eps Current Year | -0.5625 |
| Eps Forward | -0.535 |
| Eps Trailing Twelve Months | -0.6 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.094 |
| Fifty Day Average Change | -0.1379 |
| Fifty Day Average Change Percent | -0.12605119 |
| Fifty Two Week Change Percent | -55.707764 |
| Fifty Two Week High | 3.31 |
| Fifty Two Week High Change | -2.3539 |
| Fifty Two Week High Change Percent | -0.711148 |
| Fifty Two Week Low | 0.76 |
| Fifty Two Week Low Change | 0.1961 |
| Fifty Two Week Low Change Percent | 0.2580263 |
| Fifty Two Week Range | 0.76 - 3.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,090,935,000,000 |
| Float Shares | 75,379,707 |
| Forward Eps | -0.535 |
| Forward P E | -1.7871027 |
| Free Cashflow | -24,304,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 30 |
| Fullday Change | -0.014900029 |
| Fullday Change Percent | -1.5345035 |
| Fullday Price | 0.9561 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -34,821,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.06204 |
| Held Percent Institutions | 0.22114 |
| Implied Shares Outstanding | 77,795,249 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,550,620,800 |
| Last Split Factor | 1:6 |
| Long Business Summary | Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California. |
| Long Name | Cardiff Oncology, Inc. |
| Market | us_market |
| Market Cap | 74,380,032 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_10959548 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -40,076,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 103,467,681 |
| Number Of Analyst Opinions | 7 |
| Open | 0.98 |
| Operating Cashflow | -40,854,000 |
| Operating Margins | -92.45193 |
| Overall Risk | 4 |
| Phone | 858 952 7570 |
| Previous Close | 0.971 |
| Price Eps Current Year | -1.6997333 |
| Price Hint | 4 |
| Price To Book | 2.4705427 |
| Price To Sales Trailing12 Months | 146.41739 |
| Profit Margins | 0.0 |
| Quick Ratio | 3.215 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.014900029 |
| Regular Market Change Percent | -1.5345035 |
| Regular Market Day High | 0.9949 |
| Regular Market Day Low | 0.9501 |
| Regular Market Day Range | 0.9501 - 0.9949 |
| Regular Market Open | 0.98 |
| Regular Market Previous Close | 0.971 |
| Regular Market Price | 0.9561 |
| Regular Market Time | 1,792,165,664 |
| Regular Market Volume | 130,672 |
| Return On Assets | -0.46726 |
| Return On Equity | -0.94085 |
| Revenue Growth | -0.141 |
| Revenue Per Share | 0.007 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 77,795,249 |
| Shares Percent Shares Out | 0.1552 |
| Shares Short | 12,073,948 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 11,684,625 |
| Short Name | Cardiff Oncology, Inc. |
| Short Percent Of Float | 0.1585 |
| Short Ratio | 14.24 |
| Source Interval | 15 |
| State | CA |
| Symbol | CRDF |
| Target High Price | 12.0 |
| Target Low Price | 1.2 |
| Target Mean Price | 5.81429 |
| Target Median Price | 6.0 |
| Total Cash | 34,520,000 |
| Total Cash Per Share | 0.444 |
| Total Debt | 457,000 |
| Total Revenue | 508,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.6 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.54855 |
| Two Hundred Day Average Change | -0.59245 |
| Two Hundred Day Average Change Percent | -0.3825837 |
| Type Disp | Equity |
| Volume | 130,672 |
| Website | https://www.cardiffoncology.com |
| Zip | 92,121 |